Novo’s weight-loss drug Wegovy reduces risk of heart disease by 20 pct: Trial data

Novo Nordisk said on Tuesday its obesity drug Wegovy reduced the risk of a major cardiovascular event like a stroke by 20 percent in overweight or obese people with a history of heart disease, exceeding expectations from a key late-stage trial.

The results are a big boost for the Danish drugmaker’s hopes of moving beyond Wegovy’s image as a lifestyle drug. The news sent shares in Europe’s second-most valuable listed company after LVMH up more than 15 percent.

The large-scale trial called SELECT involved 17,500 patients and started almost five years ago testing if the weekly injection has medical benefits.

Ahead of the eagerly-awaited data, investors and analysts told Reuters they expected that a risk reduction of between 15 percent and 17 percent or more would be considered a positive result for the increasingly popular drug.

Novo Nordisk said in a statement it expects to file for regulatory approvals of a label indication expansion for the weekly injection in the United States and European Union this year.

The detailed results from the trial will be presented at a scientific conference later in 2023.

Wegovy has transformed the weight-loss market since its US launch in June 2021, capturing the attention of patients, investors and celebrities worldwide and boosting Novo’s shares.

The weekly injection makes patients feel full for longer and leads to an average weight loss of around 15 percent when combined with changes to diet and exercise.